Compared to Estimates, HealthEquity (HQY) Q2 Earnings: A Look at Key Metrics

HealthEquity (HQY) reported strong Q2 2025 financial results, with revenue of $325.84 million, up 8.6% year-over-year, and EPS of $1.08, significantly exceeding analyst consensus estimates by 2.2% and 17.39% respectively. The company also demonstrated robust operational growth, with key metrics such as Total HSA Assets reaching $33.14 billion and Total Accounts hitting 17.14 million, largely surpassing analyst expectations. Despite these positive financial and operational beats, HQY shares have underperformed the broader S&P 500 over the past month, returning -2% against the index's +3.8%, and currently hold a Zacks Rank #3 (Hold).

Analysis

HealthEquity (HQY) delivered a strong second quarter for fiscal 2025, exceeding analyst expectations on both top and bottom lines. The company reported revenue of $325.84 million, an 8.6% year-over-year increase that surpassed the consensus estimate by 2.2%. More notably, its EPS of $1.08 represented a significant 17.39% beat against the consensus of $0.92. This earnings strength was primarily fueled by a robust 15.3% year-over-year growth in Custodial revenue, which reached $159.88 million. Operationally, the company beat estimates for key metrics including Total HSA Assets ($33.14 billion) and Total Accounts (17.14 million). However, the report contained mixed signals, as the company fell short of analyst projections for Total HSA cash and the number of HSAs Accounts. This fundamentally strong performance contrasts with the stock's recent market action, which has seen a -2% return over the past month, underperforming the S&P 500 composite's +3.8% gain. The current Zacks Rank #3 (Hold) suggests a neutral near-term outlook, indicating a potential disconnect between the company's solid operational execution and its current market valuation.

Key Decisions for Investors

• Given the significant disconnect between strong Q2 results, including an 8.6% revenue growth and a 17.39% EPS beat, and the stock's recent -2% underperformance, investors might evaluate if the positive fundamentals are fully priced in.
• Monitor the high-growth Custodial revenue segment, which expanded 15.3% year-over-year, as its continued momentum is the critical factor for sustaining the company's overall performance and justifying a higher valuation.
• Exercise caution due to the miss on HSA Accounts and Total HSA cash estimates, along with the neutral Zacks #3 'Hold' rating, which suggests potential underlying headwinds or a need for further market confirmation before initiating new long positions.